Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 3
2005 2
2009 3
2010 1
2011 1
2012 3
2013 7
2014 6
2015 3
2016 5
2017 6
2018 6
2019 9
2020 16
2021 9
2022 12
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche.
Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho JW, Zhao X, Estivill G, Adam I, Sanchez X, McCarthy S, Schaller J, Khan Z, Ruzo A, Pastorello R, Richardson ET, Dillon D, Montero-Llopis P, Barroso-Sousa R, Forman J, Shukla SA, Tolaney SM, Mittendorf EA, von Andrian UH, Wucherpfennig KW, Hemberg M, Agudo J. Baldominos P, et al. Among authors: dillon d. Cell. 2022 May 12;185(10):1694-1708.e19. doi: 10.1016/j.cell.2022.03.033. Epub 2022 Apr 20. Cell. 2022. PMID: 35447074 Free article.
A human breast atlas integrating single-cell proteomics and transcriptomics.
Gray GK, Li CM, Rosenbluth JM, Selfors LM, Girnius N, Lin JR, Schackmann RCJ, Goh WL, Moore K, Shapiro HK, Mei S, D'Andrea K, Nathanson KL, Sorger PK, Santagata S, Regev A, Garber JE, Dillon DA, Brugge JS. Gray GK, et al. Among authors: dillon da. Dev Cell. 2022 Jun 6;57(11):1400-1420.e7. doi: 10.1016/j.devcel.2022.05.003. Epub 2022 May 25. Dev Cell. 2022. PMID: 35617956 Free PMC article.
Integrin αvβ6-TGFβ-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer.
Bagati A, Kumar S, Jiang P, Pyrdol J, Zou AE, Godicelj A, Mathewson ND, Cartwright ANR, Cejas P, Brown M, Giobbie-Hurder A, Dillon D, Agudo J, Mittendorf EA, Liu XS, Wucherpfennig KW. Bagati A, et al. Among authors: dillon d. Cancer Cell. 2021 Jan 11;39(1):54-67.e9. doi: 10.1016/j.ccell.2020.12.001. Epub 2020 Dec 31. Cancer Cell. 2021. PMID: 33385331 Free PMC article.
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.
Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, Lin JR, Hurst KE, de Oliveira Taveira M, Johnson NT, Oldham WM, Kalocsay M, Berberich MJ, Boswell SA, Kothari A, Johnson S, Dillon DA, Lipschitz M, Rodig S, Santagata S, Garber JE, Tung N, Yélamos J, Thaxton JE, Mittendorf EA, Sorger PK, Shapiro GI, Guerriero JL. Mehta AK, et al. Among authors: dillon da. Nat Cancer. 2021 Jan;2(1):66-82. doi: 10.1038/s43018-020-00148-7. Epub 2020 Dec 14. Nat Cancer. 2021. PMID: 33738458 Free PMC article.
Heterogeneity and transcriptional drivers of triple-negative breast cancer.
Jovanović B, Temko D, Stevens LE, Seehawer M, Fassl A, Murphy K, Anand J, Garza K, Gulvady A, Qiu X, Harper NW, Daniels VW, Xiao-Yun H, Ge JY, Alečković M, Pyrdol J, Hinohara K, Egri SB, Papanastasiou M, Vadhi R, Font-Tello A, Witwicki R, Peluffo G, Trinh A, Shu S, Diciaccio B, Ekram MB, Subedee A, Herbert ZT, Wucherpfennig KW, Letai AG, Jaffe JD, Sicinski P, Brown M, Dillon D, Long HW, Michor F, Polyak K. Jovanović B, et al. Among authors: dillon d. Cell Rep. 2023 Dec 26;42(12):113564. doi: 10.1016/j.celrep.2023.113564. Epub 2023 Dec 14. Cell Rep. 2023. PMID: 38100350 Free PMC article.
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer.
Wang Q, Bergholz JS, Ding L, Lin Z, Kabraji SK, Hughes ME, He X, Xie S, Jiang T, Wang W, Zoeller JJ, Kim HJ, Roberts TM, Konstantinopoulos PA, Matulonis UA, Dillon DA, Winer EP, Lin NU, Zhao JJ. Wang Q, et al. Among authors: dillon da. Nat Commun. 2022 May 31;13(1):3022. doi: 10.1038/s41467-022-30568-1. Nat Commun. 2022. PMID: 35641483 Free PMC article.
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Brown J, D'Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Anders L, Young RA, Winer E, Letai A, Barry WT, Carroll JS, Long H, Brown M, Liu XS, Meyer CA, Bradner JE, Polyak K. Shu S, et al. Among authors: dillon d. Nature. 2016 Jan 21;529(7586):413-417. doi: 10.1038/nature16508. Epub 2016 Jan 6. Nature. 2016. PMID: 26735014 Free PMC article.
Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer.
Gil Del Alcazar CR, Trinh A, Alečković M, Rojas Jimenez E, Harper NW, Oliphant MUJ, Xie S, Krop ED, Lulseged B, Murphy KC, Keenan TE, Van Allen EM, Tolaney SM, Freeman GJ, Dillon DA, Muthuswamy SK, Polyak K. Gil Del Alcazar CR, et al. Among authors: dillon da. Cancer Immunol Res. 2022 Jun 3;10(6):680-697. doi: 10.1158/2326-6066.CIR-21-0804. Cancer Immunol Res. 2022. PMID: 35446942 Free PMC article.
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP. Tolaney SM, et al. Among authors: dillon da. J Clin Oncol. 2019 Aug 1;37(22):1868-1875. doi: 10.1200/JCO.19.00066. Epub 2019 Apr 2. J Clin Oncol. 2019. PMID: 30939096 Free PMC article. Clinical Trial.
96 results